INTRODUCTION
============

At a recent course on neurotherapeutic drug discovery (sponsored by the National Institutes of Health) the keynote speaker joked that if he were trying to be rational, he would not be trying to discover neuroactive drugs. His point was that drug discovery is often much more empirical than rational. Someday, when researchers understand the biochemical mechanisms of psychiatric disease, it may be possible to discover neuroactive drugs based on rational therapeutic hypotheses. Until then, phenotypic assays provide an alternative approach. Behavior-based drug discovery is effective, but it needs to be more efficient.

Researchers can discover new drugs without understanding how they work. Neuroactive compounds including antipsychotics, antidepressants, and anxiolytics are among the top selling prescription drugs ([@B6]; [@B34]; [@B5]; [@B64]; [@B66]). We know some details about how these drugs affect different neurotransmitter signaling pathways. But nobody really knows how these simple molecules change our moods, thoughts, and emotions. Target-based approaches to central nervous system (CNS) drug discovery have been largely unsuccessful ([@B71]). However, we can discover new drugs without understanding the details of how they work ([@B38]; [@B88]). Historically, many neuroactive drugs were discovered despite totally incorrect therapeutic hypotheses ([@B82]; [@B47]; [@B28]). So, although drug discovery and molecular understanding often go hand in hand---it is mostly in that order.

New technologies are changing how researchers use phenotypic assays to discover new drugs. Low throughput assays have limited the field with small sample sizes, narrow scope and limited hypothesis testing. Many key discoveries were made essentially by chance ([@B82]; [@B28]). Now, high throughput assays are enabling a discovery-based approach that relies more on mathematical modeling and massive amounts of data (rather than theory and luck) to identify new drug leads ([@B80]). Automated screening platforms do not need mechanistic theories to generate large data sets and identify correlations between compounds and phenotype. As a result, researchers can focus on discovering drugs and drug mechanisms as separate independent endeavors. Here, we review how this data-driven approach to behavioral phenomics is accelerating the pace of neuroactive drug discovery.

HOW MANY NEUROACTIVE DRUGS ARE THERE?
=====================================

"How many neuroactive drugs are there?" is a deceptively simple question that can be surprising difficult to answer. Neuroactive drugs are difficult to classify because relationships between compound structure, target and phenotype are often unclear and poorly understood. Structure-based classification is difficult because small structural changes can drastically alter a compound's mechanism of action. Target-based classification is difficult because drug targets are often unknown. Even when *in vitro* targets are identified, their *in vivo* relevance is often unclear. One approach is to classify compounds based on behavioral phenotypes or medical utility. But most phenotype-based classifications are subjective and difficult to quantify. How do we know when a drug is an antipsychotic or an antidepressant ([@B61])? There are no known molecular causes or biomarker-based diagnostics for most mental disorders ([@B41]) and off-label prescriptions are common ([@B22]; [@B5]). So exactly how many neuroactive drugs are there?

Although the FDA lists thousands of antipsychotics, antidepressants and anxiolytics, most of these compounds fall into just a few structural classes. Consider the antipsychotics. Searching the FDALabel database for "antipsychotic" returns 1,325 hits, but most are mixtures and formulations of identical compounds ([@B89]). The same search in Drugbank returns 42 hits and most are close structural analogs of each other ([@B47]). Chemoinformatic algorithms cluster these compounds into a small number of structurally related families ([@B20]; [@B10]; **Figure [1](#F1){ref-type="fig"}**). Like antipsychotics, the antidepressants and anxiolytics show a similar pattern: There are many individual drugs, but most are structural analogs of a handful of prototypes. These data suggest that many drugs seem to discover themselves, due to the exploitation of prototype molecules ([@B81]).

![**Many drugs are structural analogs of each other.** Hierarchical cluster tree of 42 drugs labeled as "antipsychotic" in the Drugbank database. Five major families are indicated with ovals. Each family stems from a single prototype molecule.](fphar-05-00153-g001){#F1}

Most neuroactive drug prototypes were discovered during two broad time periods: pre-history and the mid-1900s. Both waves of discovery coincided with the availability of new chemical compounds alongside relatively widespread human and animal experimentation. The first wave of drugs, discovered in prehistoric times, were found by screening (ingesting) natural products in the environment. Compounds like morphine, alcohol, nicotine, and cocaine were identified based on their strange and unexpected behavioral phenotypes. The second wave of drugs, discovered in the mid-1900s, were found by screening synthetic compounds. These drugs, including the first modern anxiolytics, antipsychotics and antidepressants, were also discovered based on unexpected behavioral phenotypes.

Behavioral phenotyping is an essential part of drug discovery, but it is also the bottleneck (**Figure [2](#F2){ref-type="fig"}**). Prototype discovery often starts with the observation of an unexpected behavioral phenotype. Once a prototype has been identified, medicinal chemists generate structural analogs that themselves often have unexpected phenotypes. Researchers use these compounds to test therapeutic hypotheses and search for mechanistic understanding. When molecular targets are identified, researchers search for new ligands that trigger a new round of behavioral phenotyping. In target-based approaches, behavioral phenotyping is deferred until later in the process. Ultimately, the final step of determining efficacy in humans is also a matter of behavioral phenotyping. The process is incredibly effective and has generated most drugs that we use today. Medicinal chemistry can efficiently generate thousands of structural analogs; technologies for *in vitro* screening are ultra high-throughput. But, decades-old approaches to behavioral phenotyping throttle the drug discovery engine.

![**Behavioral phenotyping is a key bottleneck in drug discovery.** Although there is an abundance of small molecules from nature, medicinal chemistry, and target-based screening only a very small number are ever tested in behavioral assays, limiting the drug discovery process.](fphar-05-00153-g002){#F2}

WHAT DO ZEBRAFISH DO?
=====================

The zebrafish model system enables researchers to combine complex behavioral phenotyping with high-throughput chemical screening. Like humans, fish are vertebrate animals with complex brains and behaviors. But unlike humans, fish are small enough to fit in 96-well plates and they easily absorb compounds dissolved in the water. These features make zebrafish uniquely well suited for phenotype-based neuroactive drug discovery and enable researchers to scale complex behavioral assays to high-throughput formats.

A frequently asked question about behavior-based drug discovery in zebrafish is "What do zebrafish do?" Personality disorders, depression, and anxiety seem like some of the most complex phenotypes imaginable. Fish do not suffer from these feelings the same way that people do. So, the idea of using fish to discover neuroactive drugs can seem counterintuitive. We tend to think about zebrafish behavior in two different ways: where as some fish behaviors resemble some human behaviors, many others lack obvious human correlates.

Anthropomorphic assays in fish are very powerful. We immediately empathize with familiar behaviors and their circuitry and mechanisms are likely to be relatively well conserved. For example, researchers use circadian cycles in zebrafish locomotor activity to study mechanism that control sleep behaviors in humans ([@B74]; [@B96]; [@B95]; [@B77]). Researchers also use zebrafish behavior to study pain ([@B75]), fear ([@B83]; [@B2]; [@B63]), learned helplessness ([@B54]), feeding ([@B30]; [@B24]; [@B14]), courtship ([@B23]), learning ([@B90]), vision ([@B26]), hearing ([@B31]), touch ([@B57], [@B56], [@B58]), social interactions ([@B72]; [@B60]; [@B76]), anxiety ([@B84]), and decision making ([@B8]).

By contrast, it is more difficult to empathize with fish-specific phenotypes. The practical implications of understanding fundamental fish behaviors are not always obvious. And it is easy focus on their differences rather then their similarities. Nevertheless, neuroactive drugs affect fish behavior in specific and reproducible ways via conserved molecular mechanisms. Adult zebrafish, differentially change their swimming and three-dimensional tank diving behaviors in response to many neuroactive compounds ([@B19]; [@B33]; [@B85]; [@B48], [@B50]; [@B91]; [@B78]; [@B86]). In larvae, fish specific behaviors like spontaneous swimming ([@B94]), the optokinetic reflex ([@B26]) and photomotor response ([@B46]) can be used to understand neuronal signaling, rapidly identify novel neuroactive compounds and predict their mechanisms of action ([@B44]; [@B77]). The key challenge is learning how to decode complex patterns of behavior to understand which pathways are being modulated---and how they may affect human health.

A DISCOVERY-BASED APPROACH
==========================

Some of the most exciting developments in behavioral phenomics are coming from two very different models: humans and zebrafish. Compared to other animals, human behaviors are probably the most complex, variable and challenging to measure. So it is somewhat surprising that human behavioral phenomics is advancing so rapidly. One reason is that substantial investments by internet technology companies have increased the scale of digital record keeping and chemobehavioral phenotyping. Large medical databases link people's genotype, phenotype and prescription drug records. Researchers are mining these databases to identify unanticipated drug side effects and repurpose drugs for new indications ([@B25]).

Human behavioral phenomics is a powerful way to approach drug repurposing, but it cannot be used for chemical screening. Governmental and institutional regulations limit large-scale human studies to compounds that are already approved by the FDA (thankfully). Researchers will need other model organisms, like zebrafish, to systematically discover new molecular entities. Until recently, tools for high throughput behavioral phenotyping were unavailable. But new technologies are changing the drug discovery landscape.

AUTOMATED SOLUTIONS
===================

Automated technologies are making behavior-based chemical screening in zebrafish a more effective, efficient and systematic way to discover neuroactive compounds. Three aspects of automation are changing the field of behavior-based drug screening: robotics, analytics, and academic industrial collaboration. These changes are a small part of larger global trends in computing technology. As sophisticated processors, programming languages, and rapid prototyping tools become more accessible, individual scientists and small academic laboratories are innovating alongside larger biotechnology and pharmaceutical companies.

Robotic solutions are growing to meet nearly every early step of the screening process including fish breeding, sorting, and phenotyping. Robotic aquaculture racks automate feeding cycles and monitor water quality. Specialized breeding tanks produce thousands of synchronized embryos ([@B1]). Flow cytometry platforms sort zebrafish into 96-well plates. And imaging platforms automate morphological and behavioral phenotyping ([@B15]; [@B69], [@B68]; [@B3]; [@B27]; [@B92]). For example, researchers have developed an elegant and powerful (freely available) software package, FLOTE, for automated tracking of precise kinematic events in larval zebrafish ([@B15]). The software has already been used to analyze startle modulation, light adaptation, and navigation ([@B15],[@B16]; [@B17], [@B18]; [@B39]; [@B29]). The software has also been used to find compounds that modulate memory formation in larval zebrafish ([@B93]). Although not yet used for drug screening, recent advances in whole-brain functional imaging record patterns of firing activity of individual cells in large populations of neurons ([@B3], [@B4]; [@B46]; [@B65]; [@B79]; [@B73]) and will likely add massive amounts data to the behavioral pharmacology field. As behavioral datasets grow, researchers are applying new analytical approaches to explore, organize, and discover correlations between phenotypic patterns and compound treatments.

Academic-industrial partnerships are improving zebrafish phenotyping and phenotype-based approaches to drug discovery. The innovations flow both ways, from academia to industry and industry to academia. Acquifer (<http://www.acquifer.de>), a new biotech company with roots in academic automated zebrafish phenotyping, is developing network platforms for managing huge amounts of data from zebrafish phenotypic screens. Commercial imaging platforms, like the Vertebrate Automated Screening Technology marketed is based on academic innovations ([@B70], [@B68]; [@B21]). When equipment is too expensive, academic bioinstrumentation laboratories are working to develop more affordable do-it-yourself kits ([@B7]; [@B62]). As sophisticated rapid prototyping tools become more accessible (like 3D printers, open source programming languages, and cheap microcontrollers) the pace of innovation is accelerating.

SCALING BEHAVIORAL DATABASES INTO CONNECTIVITY MAPS
===================================================

Today, database-linked tools for analyzing gene expression data and behavioral data look very different. Behavioral databases tend to be designed for finding and summarizing data via search field descriptors like compound name, genes name and strain name. For example, the Zebrafish Neurophenome Database (ZND) is a publically available database designed to provide a comprehensive resource of neurobehavioral phenotypes in adult zebrafish ([@B32]; [@B49]; [@B43]). To search the ZND, a researcher uses drop-down fields to select investigator and drugs of interest to experimental results and drug effects that are often presented as textual descriptions. Similarly, large-scale mouse phenotyping projects like the Mouse Phenome Database (MPD) at The Jackson Laboratory allow users to find, visualize and analyze mouse behavioral phenotypes across different strains and conditions ([@B59]). The MPD stores a large amount of standardized, quantifiable and comparable data (like weight and grip strength). The MPD also provides a variety of tools to analyze results (including tools to find strains that best fit phenotypic criteria). But, as phenotypic databases grow ever larger, they will enable more complex data-driven queries.

Given sufficiently rich behavioral phenotyping, it should be possible to build a connectivity map to systematically identify neuroactive compounds and sort them into phenotypic classes. For example, the Connectivity Map is designed to use gene expression data as a discovery framework by allowing researchers to use gene expression signatures to query the data for closely related perturbagens ([@B52]; [@B51]). As a result, one can use the data itself to identify correlations, perform cluster analyses and identify outliers. Analyses that were originally developed for applications like speech recognition and social networking can just as easily be applied to analyzing zebrafish phenotypes. And these analyses allow new questions about large diverse data sets. We imagine that someday soon, it may be possible to query large behavioral databases with BLAST-like and speech recognition tools. This could allow researchers to identify all compounds with similar behavioral phenotypes, link genetic mutants to small molecule treatments and identify new treatments with totally novel phenotypes. Will it be possible to identify just the right pattern of fish behaviors to accurately identify drugs with complex activities in humans (like antipsychotics and antidepressants)? Future studies may provide the answer.

WHAT ARE WE LIKELY TO FIND?
===========================

Given that so few compounds have been tested in animals, large-scale behavioral screens are almost guaranteed to identify new neuroactive compounds. These studies will provide high-resolution maps of how small molecules affect the brain and behavior. But what kinds of compounds are likely to be discovered? Are we really likely to identify new compounds with new mechanisms of action? Or just more of the same kinds of drugs we already have? The data supports both arguments.

On the one hand, one could argue that behavior-based drug screening has been saturated: Multiple classes of antipsychotics, antidepressants, and anxiolytics have already been identified. One possibility is that the low throughput non-systematic approaches employed in the past have already identified all the neuroactive drugs worth discovering. Alternatively, it is interesting to speculate that compounds with antipsychotic, antidepressant and anxiolytic effects may be relatively common. If so, large-scale screens would likely identify a variety of new psychotropic drug prototypes with a range of phenotypic and mechanistic profiles, including totally new structures, mechanisms, and phenotypes.

Large zebrafish behavior-based chemical screens are already identifying a variety of new compounds. Some of first neuroactive compounds to be discovered in zebrafish, str1, and str2, were novel acetylcholinesterase inhibitors ([@B44]). These compounds were new molecular entities, but they were not first in class compounds. These compounds may provide modest advantages over current treatment options. But identifying novel structures with novel targets and mechanisms would have a greater impact. One potential way to identify compounds with novel mechanisms is to identify compounds that cause outlier phenotypes in behavioral databases. If one compound in ten thousand causes a unique behavioral phenotype, this suggests it may be working through a new (and rare) mechanism of action. For example, a new kind of light controllable rapidly reversible TrpA1 ligand, optovin, was recently discovered in just this way ([@B45]). Several novel light activated molecules have been developed using zebrafish behavioral readouts ([@B87]; [@B40]; [@B55]). This suggests that truly novel compounds are waiting to be found, if only we use the right methods to look for them.

MODIFIER SCREENS: CHEMICAL AND GENETIC MODELS
=============================================

Although wild-type phenotypes may be useful for identifying certain compounds, we can also use chemical and genetic tools to model specific disease states. These disease models combine the advantages of unbiased phenotypic screening with readouts that are specifically designed to target certain kinds of compounds. In one recent example, researchers identified a zebrafish mutant (in the Scn1a gene) and then used this model to screen for potential treatments for Dravet syndrome (caused by mutations in the homologous human gene; [@B12]). These researchers identified an FDA approved compound that suppressed the fish phenotype, suggesting that the approach may be a powerful way to identify therapeutics for this specific disorder. This work elegantly illustrates the potential for genetic models in zebrafish to identify desperately needed targeted therapeutics with potential utility in humans. One can imagine many variations on this theme. CRISP-Cas technology is revolutionizing zebrafish researchers' ability to efficiently generate knockout and knock-in models ([@B36],[@B37]; [@B9]). Transgenic overexpression models phenocopy aspects of neurodegenerative and other dominant diseases ([@B11]; [@B67]). And, due to the ease of chemical manipulations, researchers have run large-scale modifier screens in chemically treated disease models ([@B13]).

WHOLE ORGANISM PHENOTYPING: BLOOD--BRAIN BARRIER AND TOXICOLOGY
===============================================================

Researchers can expand phenotypic readouts to encompass almost any aspect the organism including blood--brain barrier (BBB), toxicity, and cardiovascular readouts. Larval zebrafish develop a functional BBB with size exclusion and transport pumps including those that are similar to mammals ([@B42]). So researchers have some reason to believe compounds with CNS activity in fish may also penetrate the BBB in mammals. Similarly, potentially toxic compounds can be screened for unwanted and unexpected toxic or cardiovascular side effects. One could potentially capture data on zebrafish development, behavior and heart rate simultaneously in a high-throughput and automated fashion. Because researchers can apply diverse phenotyping assays, zebrafish are an exciting model for toxicology in addition to drug discovery.

THE CHALLENGE OF TRANSLATING FROM FISH TO HUMANS
================================================

Despite the power of new technologies, there are substantial fundamental challenges to translating CNS drug discovery from fish to humans. Most investigational new drugs fail when they are finally tested (for efficacy) in humans ([@B71]). There are many reasons why preclinical predictions from any model system would fail to translate, but lack of rigor should not be one of them.

Inefficient animal studies contribute to publication bias, decrease scientific rigor, and limit the drug discovery process. Compared to zebrafish, studies in larger animals, like mice, are relatively expensive and require substantial amounts of test compounds. Due to these costs, some large-animal studies tend to be underpowered, which contributes to irreproducible results ([@B53]). Zebrafish enable a level of rigor and reproducibility that can be difficult to achieve in larger model organisms, simply because the assays can be easily reproduced on larger scales. Hypotheses can be tested on thousands of animals, rather than just a handful, at small cost in time and other resources. For example, treating a single mouse (at 10 mg/kg) requires approximately 100X more compound than is needed to treat a well of zebrafish (at 10 μM). When researchers increase sample size it becomes easier to find true signals amongst the noise. However, even if new compounds can be discovered with reproducible effects on zebrafish behavior, substantial challenges remain to translate these discoveries for improving human health.

Many compounds work in humans, many work in zebrafish, and some fraction is likely to work in both--although the exact level of overlap is difficult to predict (**Figure [3](#F3){ref-type="fig"}**). Humans and zebrafish are closely related ([@B35]), but there are many differences at the phenotypic, neuronal network, and molecular levels. When a new bioactive compound is first discovered in zebrafish, it will be difficult to predict its potential therapeutic utility in humans. Many compounds that appear to work well in mice and other animal models subsequently fail to translate to humans. The same will surely be true of zebrafish. The problem is especially relevant in neuropharmacology, where CNS disorders are poorly understood and difficult to model. Despite the challenges, in the upcoming years we are likely to see at least a few compounds identified in zebrafish screens translate from bench to bedside.

![**How many drugs work in both humans and zebrafish? Not all drugs that work in zebrafish will also work in humans.** Because so many more compounds can be screened in zebrafish, it is likely that some will translate to the clinic. However, the precise level of overlap (indicated by X) is difficult to predict.](fphar-05-00153-g003){#F3}
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